(90)Y-Ibritumomab tiuxetan followed by reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with advanced follicular lymphoma

RIC HSCT is a potentially curative therapeutic option for patients with advanced FL but disease relapse remains the most common cause of failure. Radioimmunoconjugates administered prior to RIC allogeneic HSCT may enhance cytoreduction and allow more time for graft versus lymphoma effect to develop...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Abou-Nassar, Karim E., Stevenson, Kristen E., Antin, Joseph H., McDermott, Kathleen, Ho, Vincent T., Cutler, Corey S., LaCasce, Ann S., Jacobsen, Eric D., Fisher, David C., Soiffer, Robert J., Alyea, Edwin P., Koreth, John, Freedman, Arnold S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3139703/
https://ncbi.nlm.nih.gov/pubmed/21258420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2010.339
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi